Insider Ledger

BBTX insider buying and SEC filings, explained

Bambusa Therapeutics, Inc. · CIK 2044950

Tracked: Forms 3/4/5, 8-K, NT · All filings on sec.gov

Company profile

Exchanges
Nasdaq
Industry (SIC)
Biological Products, (No Diagnostic Substances)
State of incorporation
DE
Fiscal year end
Dec 31

Insider activity in the last 12 months

Bought
$12.0M
Insiders who bought
2
Sold (not marked 10b5-1)
$0
Planned sales (10b5-1)
$0

Insider purchases and sales, last 12 months

TradedTypeWhat was filedSource
Nov 2, 2026Purchase (code P)Salvia Investment GmbH (10% owner) bought 375,000 shares at $16.00 ($6.0M), reported as a purchase (code P). Holdings up 4% to 9,264,301 shares. Not marked as a 10b5-1 plan trade.SEC filing
Filed Nov 2, 2026, 4:07 PM ET
Nov 2, 2026Purchase (code P)Helmut Wolfgang Jeggle (Director and 10% owner) bought 375,000 shares indirectly at $16.00 ($6.0M), reported as a purchase (code P). Indirect holdings up 4% to 9,264,301 shares. Not marked as a 10b5-1 plan trade.SEC filing
Filed Nov 2, 2026, 4:06 PM ET

4 routine transactions (such as grants, option exercises or tax withholding) are not listed.

Cluster buys

2 insiders bought in 30 days

$12.0M in purchases since Nov 2, 2026 · Purchases traded Nov 2, 2026 to Nov 2, 2026 · Active

InsiderValueTradedSource
Salvia Investment GmbH (10% owner)$6.0MNov 2, 2026SEC filing
Helmut Wolfgang Jeggle (Director)$6.0MNov 2, 2026SEC filing

Red flags

No red flags in the last 12 months.

Key events

No key events in the last 12 months.

8-K filings, last 12 months

FiledItemsTagSource
Nov 2, 2026, 6:19 PM ET
8-K		Bylaws or fiscal-year change (Item 5.03)
Reg FD disclosure (Item 7.01)		SEC filing

Red flags are objective triggers only: the item or form filed, never an opinion.

Follow BBTX in the Insider Ledger app

A plain-English brief of insider purchases, 8-Ks and red flags at the companies you pick. No account needed.

Get the app